Cardiovascular, Hormone, Obesity & Overweight
Conditions
Keywords
Overweight, Obesity, Pre-menopause, Post-menopause, Zumba Training, Cardiometabolic Health, Hormonal Adaptations, Lipid Profile
Brief summary
This study aims to evaluate the effects of a 4 month Zumba training program on cardiometabolic, hormonal, inflammatory, hepatic, renal, and functional parameters in overweight and obese women. Participants will be classified according to menopausal status (pre- or post-menopausal) and randomly assigned to an exercise group or a non-exercise control group.
Detailed description
Overweight and obesity are associated with metabolic dysregulation, hormonal imbalance, chronic inflammation, and reduced physical capacity. Zumba training is a dance-based aerobic exercise that can improve cardiovascular fitness, energy expenditure, and adherence to physical activity programs. This study will assess the effects of a 4 month Zumba training program (4 sessions per week, 60 minutes per session) on: Body composition and anthropometric measures, Aerobic capacity, Hormonal profile, Lipid profile, Inflammatory biomarkers, Liver enzymes, Renal function markers, Electrolytes, Muscle enzymes, Pre- and post-training measurements will be taken under standardized conditions.
Interventions
BEHAVIORALZumba training
Participants assigned to the experimental groups will perform a supervised Zumba training program for 10 weeks, with 4 sessions per week, each session lasting 60 minutes. Sessions will include a standardized warm-up (10 minutes), choreographed dance-based aerobic sequences performed at moderate intensity (40 minutes), and a cool-down with stretching (10 minutes).
Sponsors
High Institute of Sports and Physical Education of Kef
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female, aged 18-65 years * BMI ≥ 25 kg/m² * Pre-menopausal or post-menopausal (classified clinically) * Voluntary written informed consent
Exclusion criteria
* Hormonal therapy or weight-loss medications * Endocrine diseases or chronic illness * Recent intense physical training (\<48 hours before baseline)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creatine Phosphokinase (CPK) | Baseline and after 4 months of training. | Serum CPK concentration measured in U/L, indicator of muscle damage. |
| Calcium (Ca) | Baseline and after 4 months of training. | Serum calcium concentration measured in mg/dL. |
| Magnesium (Mg) | Baseline and after 4 months of training. | Serum magnesium concentration measured in mg/dL. |
| Phosphate (PO₄) | Baseline and after 4 months of training. | Serum phosphate concentration measured in mg/dL. |
| Bilirubin Total | Baseline and after the 4 months of the intervention. | Total serum bilirubin concentration measured in mg/dL. |
| Bilirubin Direct | Baseline and after the 4 months of the intervention. | Direct (conjugated) serum bilirubin concentration measured in mg/dL. |
| Body Mass Index (BMI) | Baseline and after 4 months of Zumba intervention. | BMI calculated as weight (kg) divided by height squared (m²). |
| Body Fat Percentage | Baseline and after 4 months of Zumba intervention. | Total body fat measured by digital scale (Tanita BC-533). |
| Waist Circumference | Baseline and after 4 months of Zumba intervention. | Measured at the narrowest point between the rib cage and iliac crest using a tape measure. |
| Waist-Hip Ratio | Baseline and after 4 months of Zumba intervention. | Calculated by dividing waist circumference by hip circumference. |
| Hip Circumference | Baseline and after 4 months of Zumba intervention. | Measured at the widest point of the hips using a tape measure. |
| Prolactin | Baseline and after 4 months of the intervention. | Serum prolactin concentration (ng/mL). |
| Testosterone | Baseline and after 4 months of the intervention. | Serum testosterone concentration (ng/dL). |
| Cortisol | Baseline and after 4 months of the intervention. | Serum cortisol concentration (µg/dL). |
| Progesterone | Baseline and after 4 months of the intervention. | Serum progesterone concentration (ng/mL). |
| Estradiol | Baseline and after 4 months of the intervention. | Serum estradiol concentration (pg/mL). |
| Follicle-Stimulating Hormone (FSH) | Baseline and after 4 months of the intervention. | Serum FSH concentration (mIU/mL). |
| Luteinizing Hormone (LH) | Baseline and after 4 months of the intervention. | Serum LH concentration (mIU/mL). |
| Thyroid Stimulating Hormone (TSH) | Baseline and after 4 months of the intervention. | Serum TSH concentration (µIU/mL). |
| Free Thyroxine (FT4) | Baseline and after 4 months of the intervention. | Serum free T4 concentration (ng/dL). |
| Parathyroid Hormone (PTH) | Baseline and after 4 months of the intervention. | Serum PTH concentration (pg/mL). |
| Total Cholesterol | Baseline and after 4 months of the intervention. | Serum total cholesterol concentration (mg/dL). |
| High-Density Lipoprotein (HDL) Cholesterol | Baseline and after 4 months of the intervention. | Serum HDL cholesterol concentration (mg/dL). |
| Low-Density Lipoprotein (LDL) Cholesterol | Baseline and after 4 months of the intervention. | Serum LDL cholesterol concentration (mg/dL). |
| Triglycerides | Baseline and after 4 months of the intervention. | Serum triglyceride concentration (mg/dL). |
| C-Reactive Protein (CRP) | Baseline and after 4 months of the intervention. | Serum CRP concentration (mg/L). |
| Erythrocyte Sedimentation Rate (ESR) | Baseline and after 4 months of the intervention. | ESR measured in mm/hr. |
| Complete Blood Count (CBC) | Baseline and after 4 months of the intervention. | Includes neutrophils, lymphocytes, monocytes, eosinophils, basophils (cells/µL). |
| Alanine Aminotransferase (ALT) | Baseline and after 4 months of the intervention. | Serum ALT concentration measured in U/L. |
| Aspartate Aminotransferase (AST) | Baseline and after 4 months of the intervention. | Serum AST concentration measured in U/L. |
| Alkaline Phosphatase (ALP) | Baseline and after 4 months of the intervention. | Serum ALP concentration measured in U/L. |
| Gamma-Glutamyl Transferase (GGT) | Baseline and after 4 months of the intervention. | Serum GGT concentration measured in U/L. |
| Lactate Dehydrogenase (LDH) | Baseline and after the 4 months of the intervention. | Serum LDH concentration measured in U/L. |
| Creatinine | Baseline and after 4 months of the intervention. | Serum creatinine concentration measured in mg/dL, indicator of kidney function. |
| Urea | Baseline and after 4 months of the intervention. | Serum urea concentration measured in mg/dL, indicator of kidney function. |
| Uric Acid | Baseline and after 4 months of the intervention. | Serum uric acid concentration measured in mg/dL, indicator of kidney function. |
| Sodium (Na) | Baseline and after 4 months of the intervention. | Serum sodium concentration measured in mmol/L. |
| Potassium (K) | Baseline and after 4 months of the intervention. | Serum potassium concentration measured in mmol/L. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood Pressure (Systolic and Diastolic) | Baseline and after 4 months of Zumba intervention. | Measured using an automated arm cuff (Omron BP652). |
| 6-Minute Walk Test (6MWT) Distance | Baseline and after 4 months of Zumba intervention. | Distance walked in 6 minutes on a 30-meter straight corridor. |
| Resting Heart Rate | Baseline and after 4 months of Zumba intervention. | Measured using automated device (Omron BP652). |
Contacts
Primary ContactWissal Abassi, Dr
Backup Contactwissal Abassi, Dr
Outcome results
None listed